Dr. Reddy's Laboratories gains as its arm enters into definitive agreement with Haleon plc

Dr. Reddy's Laboratories is currently trading at Rs. 6198.15, up by 129.70 points or 2.14% from its previous closing of Rs. 6068.45 on the BSE.

The scrip opened at Rs. 6037.95 and has touched a high and low of Rs. 6235.90 and Rs. 5999.85 respectively. So far 26128 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 6505.50 on 28-Feb-2024 and a 52 week low of Rs. 5005.00 on 28-Jun-2023.

Last one week high and low of the scrip stood at Rs. 6235.90 and Rs. 5958.05 respectively. The current market cap of the company is Rs. 103601.24 crore.

The promoters holding in the company stood at 26.65%, while Institutions and Non-Institutions held 47.44% and 10.55% respectively.

Dr. Reddy's Laboratories’ subsidiary --Dr. Reddy's Laboratories SA has entered into definitive agreement with Haleon plc to purchase the shares of Northstar Switzerland SARL for GBP 500 million. This significant move will see Dr Reddy's take ownership of Haleon's global portfolio of Nicotine Replacement Therapy (NRT) brands, excluding the United States.

Additional brand names such as Nicabate, Thrive, and Habitrol will also be part of the acquisition. The portfolio to be acquired consists of Nicotinell, a global leader in the NRT category with an extensive footprint in over 30 countries spanning Europe, Asia including Japan, and Latin America, and local market-leading brand names of the product – Nicabate in Australia, Thrive in Canada, and Habitrol in New Zealand and Canada.

The business portfolio generated approximately GBP 217 million in revenue in 2023. The proposed acquisition will be inclusive of all formats such as lozenge, patch, gum as well as pipeline products, in all applicable global markets outside of the United States.

Nicotinell is the second biggest brand globally (excluding the United States) in the NRT category. It holds the first or second position in 14 of the top 17 global markets, with the lozenge/mini lozenge format holding top position globally. The complete transaction is set to close by early Q42024, following regulatory approvals and customary conditions.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.